Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 97 Results

Title
Intervention Indication Therapeutic Area Year Actions
Abatacept for treating idiopathic inflammatory myopathies Abatacept (Orencia) Idiopathic inflammatory myopathies Immunology , Musculoskeletal System 2022 View  |  Download
Abatacept with a calcineurin inhibitor and methotrexate for prophylaxis of acute graft versus host disease Abatacept (Orencia) Graft versus host disease (GvHD) Immunology 2022 View  |  Download
ABP 959 for treating paroxysmal nocturnal
haemoglobinuria
ABP 959 Paroxysmal nocturnal haemoglobinuria (PNH) Haematology 2022 View  |  Download
Acalabrutinib with bendamustine and rituximab for treating previously untreated mantle cell lymphoma Acalabrutinib (Calquence; ACP-196) , Bendamustine (Treanda; EP-3102; Levact; Ribomustin; bendamustine hydrochloride monohydrate; bendamustine hydrochloride) , Rituximab (MabThera; Rituxan; RG 105) Mantle cell lymphoma Haematological Cancer and Lymphomas 2022 View  |  Download
Amivantamab with chemotherapy for previously untreated advanced EGFR exon 20 insertion mutations positive non-small cell lung cancer Amivantamab (JNJ-6372; JNJ-61186372) , Chemotherapy Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
AR101 for peanut allergy in children aged 1 – 3 years Palforzia (AR101) Peanut allergy Immunology 2022 View  |  Download
ASTX727 for acute myeloid leukaemia ASTX727 Acute lymphoblastic leukaemia (ALL) Haematological Cancer and Lymphomas 2022 View  |  Download
Atezolizumab adjuvant therapy for treating renal cell carcinoma in people at high risk of developing metastasis following nephrectomy Atezolizumab (Tecentriq; MPDL3280A) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
1 2 3 9 10
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications